Sirukumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sirukumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IL6
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6450H9926N1690O1998S46
Molar mass 144.6 kg/mol
 NYesY (what is this?)  (verify)

Sirukumab (INN, USAN) (developmental code name CNTO-136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor[2]

Clinical trials[edit]

Rheumatoid arthritis[edit]

It has started clinical trials.[3] and reported some phase II results.[2]

In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[4] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[5]

Other[edit]

The drug is currently in phase II clinical trials for the treatment of depression.[6]

See also[edit]

References[edit]